分组1 - Acadia Healthcare reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, compared to earnings of $0.64 per share a year ago [1] - The earnings surprise for the quarter was +164.15%, and the company has surpassed consensus EPS estimates in all four of the last quarters [2] - Revenues for the quarter were $821.46 million, surpassing the Zacks Consensus Estimate by 2.85%, and up from $774.24 million year-over-year [3] 分组2 - Acadia Healthcare shares have increased approximately 21% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.7% [4] - The current consensus EPS estimate for the upcoming quarter is $0.27 on revenues of $798.56 million, and for the current fiscal year, it is $1.76 on revenues of $3.4 billion [8] - The Medical - Hospital industry, to which Acadia Healthcare belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [9]

Core Viewpoint - Acadia Healthcare reported strong fourth-quarter earnings and sales, exceeding consensus estimates, driven by improved volume growth and operational performance [2][3][4]. Earnings Snapshot - Fourth-quarter adjusted earnings were 7 cents, beating the consensus of 6 cents - Sales reached $821.46 million, surpassing the consensus of $800.07 million, primarily due to improved volume growth [2]. Performance Metrics - Year-over-year sales increased by 6.1% - Same-facility revenue rose by 4.4%, supported by a 3.1% increase in patient days and a 1.3% increase in revenue per patient day - Same-facility admissions grew by 2.5% - Facilities closed over the last 12 months negatively impacted reported revenue growth by 2% - Revenue from acute inpatient psychiatric facilities was $451 million, marking a 10% year-over-year increase [3]. Fourth Quarter Volumes and EBITDA - Acute inpatient volumes increased by 6%, driven by expanded capacity from new and existing facilities - Adjusted EBITDA for the quarter was $99.8 million, down from $153.1 million in the prior-year period due to higher expenses [4]. Fiscal 2026 Guidance - Acadia projects 2026 revenues between $3.37 billion and $3.45 billion, compared to the consensus of $3.41 billion - Expected adjusted earnings are between $1.30 and $1.55 per share, versus the consensus of $1.75 - Outlook assumes same-facility volume growth of 0%-1% and revenue per patient day growth of 2%-3% [5]. First Quarter 2026 Guidance - For the first quarter of 2026, adjusted earnings are expected to be between 25 and 30 cents, compared to the Wall Street estimate of 31 cents - Sales are forecasted to be between $820 million and $830 million, compared to the consensus of $805.59 million [6]. Management Commentary - CEO Debbie Osteen highlighted improved volume growth and year-over-year revenue growth of 6% - Emphasized priorities include steady leadership, operational discipline, and positioning the company for long-term success [7]. Technical Analysis - The stock is trading 22.71% above its 20-day simple moving average, indicating strong short-term momentum - The RSI is at 44.45, suggesting neutral territory, while MACD at 0.15 indicates bearish pressure [7][8]. Analyst Consensus & Recent Actions - The stock carries a Buy Rating with an average price target of $21.27 - Recent price action shows Acadia Healthcare shares were up 23.06% at $21.13 - Key resistance is at $22.50 and key support at $19.50 - Recent analyst actions include Guggenheim maintaining a Buy rating with a target of $22.00 and Jefferies downgrading to Hold with a target of $15.00 [9].

Group 1 - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by approximately 1% on Wednesday [1] - Acadia Healthcare reported quarterly earnings of 7 cents per share, surpassing the analyst consensus estimate of 6 cents per share [1] - The company achieved quarterly sales of $821.459 million, exceeding the analyst consensus estimate of $800.065 million [1] - Following the earnings report, Acadia Healthcare shares surged by 23.5% to $21.27 on Wednesday [1]

Financial Data and Key Metrics Changes - The company reported revenue of $821.5 million for Q4 2025, a 6.1% increase year-over-year [14] - Full year 2025 revenue reached $3.31 billion, reflecting a 5% increase over the prior year [15] - Adjusted EBITDA for Q4 was $99.8 million, with full year adjusted EBITDA at $608.9 million, near the upper end of guidance [15][16] - Same-facility revenue grew 4.4% year-over-year, driven by a 1.3% increase in revenue per patient day and a 3.1% increase in patient days [16] Business Line Data and Key Metrics Changes - The company added 181 beds in Q4 2025, totaling 1,089 beds added for the full year, exceeding guidance [17][18] - Startup losses related to newly opened facilities were $12.8 million in Q4, compared to $11.2 million in Q4 2024 [16] - The company plans to add between 400 and 600 new beds in 2026, primarily through new facilities [18] Market Data and Key Metrics Changes - The company is facing a $25 million-$30 million annual EBITDA impact due to New York's decision to limit Medicaid patients to in-state facilities [21][72] - The company anticipates a 2%-3% increase in same facility revenue per patient day for 2026, despite a decrease in Medicaid supplemental payment revenue [20] Company Strategy and Development Direction - The focus is on operational excellence and execution, with a commitment to support teams in the field [5][10] - The company is evaluating service lines comprehensively to ensure alignment with long-term value creation [11] - There is a strong emphasis on quality and patient safety, with a commitment to improve operational discipline and management quality [8][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong demand for behavioral health services and the company's ability to meet that need [10][24] - The company expects full year 2026 revenue to be between $3.37 billion and $3.45 billion, with adjusted EBITDA of $575 million-$610 million [19] - Management acknowledged challenges in the operating environment but remains optimistic about unlocking EBITDA and free cash flow potential [10][24] Other Important Information - The company invested $93 million in CapEx in Q4 2025, totaling $572 million for the full year, which was nearly $50 million favorable to prior guidance [17] - The company is focused on improving relationships with referral sources and enhancing operational performance at the facility level [53] Q&A Session Summary Question: Status of the value creation review with outside advisors - Management confirmed that the review is ongoing and focused on immediate progress while also looking for long-term value opportunities [27][28] Question: Growth algorithm expectations in the current environment - Management believes the growth algorithm remains unchanged, with strong demand expected to continue [30] Question: Timeframe for realizing embedded earnings from development activity - Management indicated that the realization of the $200 million incremental EBITDA opportunity is expected within five years [35] Question: Addressing pressure on average length of stay from managed Medicaid - Management stated that they maintain stable length of stay and advocate for patients to ensure appropriate care [42] Question: Plans to rebuild trust with referral sources - Management emphasized the importance of delivering high-quality care consistently to rebuild trust with referral sources [52] Question: Long-term CapEx strategy - Management indicated a focus on improving existing facilities and being disciplined with capital expenditures moving forward [60][62] Question: Impact of California's new staffing requirements - Management expects a $4 million EBITDA impact from new staffing guidelines, which is embedded in guidance [78] Question: Observations on the ramp of new facilities - Management noted that the ramping of new facilities is being assessed on a case-by-case basis, with plans to improve processes for future openings [85]

Financial Data and Key Metrics Changes - The company reported revenue of $821.5 million for Q4 2025, a 6.1% increase year-over-year [14] - Full year 2025 revenue reached $3.31 billion, reflecting a 5% increase over the previous year [15] - Adjusted EBITDA for Q4 was $99.8 million, with full year adjusted EBITDA at $608.9 million, near the upper end of guidance [15][16] - Same-facility revenue grew 4.4% year-over-year, driven by a 1.3% increase in revenue per patient day and a 3.1% increase in patient days [16] Business Line Data and Key Metrics Changes - The company added 181 beds in Q4 2025, totaling 1,089 beds added for the full year, exceeding guidance [17][18] - Startup losses related to new facilities were $12.8 million in Q4, compared to $11.2 million in Q4 2024 [16] - The company plans to add between 400 and 600 new beds in 2026, primarily through new facilities [18] Market Data and Key Metrics Changes - The company is facing a $25 million-$30 million annual EBITDA impact due to New York's decision to restrict Medicaid patients from receiving care in out-of-state facilities [21][72] - The company anticipates a 2%-3% increase in same-facility revenue per patient day for 2026, despite a decrease in Medicaid supplemental payment revenue [20] Company Strategy and Development Direction - The focus is on operational excellence and execution, with a commitment to quality management at all levels [7][10] - The company is expanding its presence through joint ventures with leading health systems, tailoring partnerships to local community needs [9] - Capital allocation will be disciplined, with a focus on projects that stand on their own merits [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong demand for behavioral health services and the company's ability to meet that need [24] - The company is focused on improving operational discipline and leveraging data for better decision-making [56] - Management expects to generate positive free cash flow in 2026, with a significant reduction in CapEx [22][60] Other Important Information - The company has invested $93 million in CapEx in Q4 2025, totaling $572 million for the full year, which was nearly $50 million favorable to prior guidance [17] - The company is actively working to backfill occupancy in markets affected by regulatory changes [72] Q&A Session Summary Question: Update on the value creation review with outside advisors - Management confirmed that the review is ongoing and focused on immediate performance and long-term value creation [27][28] Question: Growth algorithm in the current environment - Management sees no change in the growth algorithm, with strong demand expected to continue [30] Question: Timeline for realizing embedded earnings from development activity - Management indicated that the realization of $200 million in incremental EBITDA is expected within five years [35] Question: Addressing pressure on average length of stay from managed Medicaid - Management stated that they maintain stable length of stay and advocate for patients to ensure appropriate care [42] Question: Plans to rebuild trust with referral sources - Management emphasized the importance of delivering high-quality care and maintaining strong relationships with referral sources [52] Question: Long-term CapEx strategy - Management plans to focus on existing facilities and be disciplined with capital expenditures moving forward [60][62] Question: Impact of California's new staffing requirements - Management expects a $4 million EBITDA impact from new staffing guidelines, which is embedded in guidance [78] Question: Performance of new facilities and ramp pacing - Management identified common themes affecting the ramp-up of new facilities and plans to improve processes for future openings [84]

Financial Data and Key Metrics Changes - The company reported Q4 2025 revenue of $821.5 million, a 6.1% increase year-over-year. Full-year revenue for 2025 was $3.31 billion, reflecting a 5% increase over the prior year [13][14] - Adjusted EBITDA for Q4 was $99.8 million, with full-year adjusted EBITDA at $608.9 million, near the upper end of guidance [13][14] - Same-facility revenue grew 4.4% year-over-year in Q4, driven by a 1.3% increase in revenue per patient day and a 3.1% increase in patient days [14] Business Line Data and Key Metrics Changes - The company added 181 beds in Q4 2025, totaling 1,089 beds added for the full year, exceeding guidance [15][16] - Startup losses related to new facilities were $12.8 million in Q4, compared to $11.2 million in Q4 2024 [14] - The company expects to add between 400 and 600 new beds in 2026, primarily through new facilities nearing completion [16] Market Data and Key Metrics Changes - The company has expanded its footprint to over 12,500 beds, serving 84,000 patients per day [22] - The New York Medicaid program changes are expected to impact same-facility growth by approximately 350 basis points [18][19] Company Strategy and Development Direction - The focus is on operational excellence and execution, with a commitment to quality management and accountability [5][6] - The company is evaluating service lines comprehensively to ensure alignment with long-term value creation [10] - Joint ventures with leading health systems are being pursued to expand presence and better serve local communities [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong demand for behavioral health services and the potential to unlock significant EBITDA and free cash flow from existing facilities [9][12] - The company anticipates a challenging environment but remains focused on delivering quality care and improving operational performance [22] - Management expects full-year 2026 revenue to be between $3.37 billion and $3.45 billion, with adjusted EBITDA of $575 million to $610 million [17] Other Important Information - The company is committed to maintaining strong relationships with partners and aligning staffing with patient needs [6][10] - Regulatory matters are being addressed, with a focus on recruitment and retention of qualified staff [11] Q&A Session Summary Question: Status of the value creation review - Management confirmed that the value creation review is ongoing and focused on immediate progress while also considering long-term value [26][27] Question: Growth algorithm in the current environment - Management believes the growth algorithm remains unchanged, with strong demand expected to continue [29] Question: Timeline for realizing embedded earnings from development activity - Management indicated that the realization of the $200 million incremental EBITDA opportunity is expected within five years [34][35] Question: Addressing average length of stay pressures from managed Medicaid - Management acknowledged the challenges but emphasized stable length of stay metrics and advocacy for patient needs [41][43] Question: Plans to rebuild trust with referral sources - Management highlighted the importance of consistent high-quality care and effective communication with referral sources [52][54] Question: Long-term CapEx strategy - Management indicated a significant reduction in CapEx for 2026, focusing on existing facilities and potential M&A opportunities [60][63] Question: Impact of California's new staffing requirements - Management expects a $4 million EBITDA impact from California's new staffing guidelines, which is included in guidance [79][80] Question: Volume growth expectations excluding specific headwinds - Management anticipates underlying core growth in the 1%-2% range, with additional contributions from ramping facilities [114]

Core Insights - The article highlights the investment strategies of Paul Franke, a seasoned investor with 39 years of trading experience, emphasizing his contrarian stock selection style and the development of a system called "Victory Formation" for identifying stocks based on supply/demand imbalances [1] Group 1: Investment Strategies - Paul Franke suggests using 10% or 20% stop-loss levels on individual stock choices and advocates for a diversified portfolio of at least 50 well-positioned stocks to achieve consistent outperformance in the stock market [1] - The "Bottom Fishing Club" articles focus on deep value candidates or stocks that are experiencing significant upward momentum reversals [1] - The "Volume Breakout Report" articles discuss positive trend changes supported by strong price and volume trading actions [1] Group 2: Performance Recognition - Franke was consistently ranked among the top investment advisors nationally during the 1990s and achieved a 1 ranking in the Motley Fool® CAPS stock picking contest in 2008 and 2009, out of over 60,000 portfolios [1] - As of December 2025, he was ranked in the Top 4% of bloggers by TipRanks® for 12-month stock picking performance based on suggestions made over the last five years [1]

Core Insights - The article highlights the investment strategies of Paul Franke, a seasoned investor with 39 years of trading experience, emphasizing his contrarian stock selection style and the development of a system called "Victory Formation" for identifying stocks based on supply/demand imbalances [1] Group 1: Investment Strategies - Paul Franke suggests using 10% or 20% stop-loss levels on individual stock choices and advocates for a diversified portfolio of at least 50 well-positioned stocks to achieve consistent outperformance in the stock market [1] - The "Bottom Fishing Club" articles focus on deep value candidates or stocks that are experiencing significant upward momentum reversals [1] - The "Volume Breakout Report" articles discuss positive trend changes supported by strong price and volume trading actions [1] Group 2: Performance Recognition - Franke was consistently ranked among the top investment advisors nationally during the 1990s and achieved a 1 ranking in the Motley Fool® CAPS stock picking contest during parts of 2008 and 2009, out of over 60,000 portfolios [1] - As of December 2025, he was ranked in the Top 4% of bloggers by TipRanks® for 12-month stock picking performance based on suggestions made over the last five years [1]

Core Viewpoint - Engine Capital Management has significantly reduced its stake in Acadia Healthcare, indicating potential concerns about the company's performance and market confidence [2][7]. Company Overview - Acadia Healthcare operates a large network of behavioral health facilities, focusing on mental health and addiction treatment across the U.S. and Puerto Rico [5][8]. - The company reported a total revenue of $3.27 billion and a net income of $107.36 million for the trailing twelve months (TTM) [4]. Recent Transaction Details - On February 17, 2026, Engine Capital Management sold 2,256,741 shares of Acadia Healthcare, valued at approximately $42.70 million based on the average closing price in Q4 2025 [1][2]. - Following this transaction, the value of Acadia Healthcare's stake decreased by $59.35 million, reflecting both trading activity and price changes [2]. Stock Performance - As of February 17, 2026, Acadia Healthcare's shares were priced at $16.42, representing a 60.04% decline over the past year, significantly underperforming compared to the S&P 500's approximate 13% gain during the same period [7][4]. Future Outlook - Acadia Healthcare reaffirmed its 2025 guidance, projecting revenue between $3.28 billion and $3.30 billion, adjusted EBITDA of $601 million to $611 million, and adjusted EPS of $1.94 to $2.04 [10]. - The company operates 278 facilities with around 12,500 beds, indicating a strong operational scale in the behavioral health sector [10]. Leadership and Market Challenges - Recent leadership changes, including the return of Debbie Osteen as CEO, add uncertainty as the board seeks to enhance shareholder value [11]. - The company faces challenges from Medicaid financing changes and broader macroeconomic pressures, which may impact its operational stability [11].

Core Viewpoint - Acadia Healthcare Company, Inc. will participate in multiple investor conferences in March 2026, showcasing its position as a leading provider of behavioral healthcare services in the U.S. [1] Group 1: Investor Conferences - The company will participate in the Raymond James & Associates' 47th Annual Institutional Investors Conference from March 1-4, 2026, with a presentation on March 2 at 11:35 a.m. ET [1] - Acadia will also attend the Leerink Partners 2026 Global Healthcare Conference from March 9-12, 2026, presenting on March 9 at 3:40 p.m. ET [1] - Additionally, the company will be part of the Barclays 28th Annual Global Healthcare Conference from March 10-12, 2026, with a presentation scheduled for March 10 at 12:00 p.m. ET [1] Group 2: Company Overview - As of September 30, 2025, Acadia operates 278 behavioral healthcare facilities with approximately 12,500 beds across 40 states and Puerto Rico [1] - The company employs around 25,500 staff and serves over 82,000 patients daily, making it the largest stand-alone behavioral healthcare company in the U.S. [1] - Acadia provides a range of behavioral healthcare services in various settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics [1]